AstraZeneca is getting rights to a Sino Biopharmaceutical drug that provides a twin mechanism to deal with power obstructive pulmonary illness, or COPD. It’s the identical method as an FDA-approved drug that Merck acquired final yr in a multi-billion greenback deal.
The submit AstraZeneca Turns to China for Molecule That Would possibly Prime New Merck COPD Drug appeared first on MedCity Information.
